<?xml version="1.0" encoding="UTF-8"?>
<p>Dolutegravir was provided by ViiV Healthcare Ltd (Research Triangle Park, NC, USA). Elvitegravir was obtained from Gilead Sciences Inc. (Foster City, CA, USA). Lamivudine was obtained from the NIH AIDS Research and Reference Reagent Program (
 <ext-link ext-link-type="uri" xlink:href="http://www.aidsreagent.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.aidsreagent.org</ext-link>). HIV-1 strains from 6 and 11 patients from singleton/small and large clusters, respectively, were used to infect CBMCs at a similar moi of 0.1, i.e. 1 × 10
 <sup>6</sup> TCID
 <sub>50</sub> per 10 × 10
 <sup>6</sup> CBMCs, based on p24 and RT assays.
 <xref rid="dkx118-B57" ref-type="bibr">
  <sup>57</sup>
 </xref> Viruses were serial passaged in CBMCs in the presence of escalating concentrations of dolutegravir, elvitegravir and/or lamivudine over 24–36 weeks, as previously described.
 <xref rid="dkx118-B58" ref-type="bibr">
  <sup>58</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B59" ref-type="bibr">
  <sup>59</sup>
 </xref> RT activity in culture supernatants was quantified weekly to monitor viral replication of individual viral variants in the presence and absence of drug pressure, adjusting incremental increases in drug concentrations if RT activity assays exceeded 100 000 cpm.
 <xref rid="dkx118-B58" ref-type="bibr">
  <sup>58</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B59" ref-type="bibr">
  <sup>59</sup>
 </xref> At each passage, aliquots of cell-free supernatant were stored at −70°C for further genotypic analysis.
</p>
